A new imaging technology can distinguish cancerous tissue from healthy cells by detecting ultra-weak light signals. It relies on nanoparticles that bind to tumor markers, making cancerous areas easier to identify. The system is far more sensitive than existing tools and could speed up cancer screening. Scientists believe it may help detect tumors earlier and reduce delays in diagnosis.
The imaging system is designed to detect extremely weak signals from surface-enhanced Raman scattering (SERS) nanoparticles that are engineered to attach to tumor markers. Once these nanoparticles are applied to a sample or to the area being examined, the system reads their Raman signal and automatically highlights regions that are more likely to contain tumor tissue.
"Traditional methods for cancer-related diagnosis are time-consuming and labor-intensive because they require staining tissue samples and having a pathologist look for any abnormalities," said research team leader Zhen Qiu from the Institute for Quantitative Health Science and Engineering (IQ), Michigan State University. "While our system would not immediately replace pathology, it could serve as a rapid screening tool to accelerate diagnosis."
This technology could eventually enable portable or intraoperative devices that enable clinicians to detect cancers at earlier stages, improve the accuracy of biopsy sampling and monitor disease progression through less invasive testing.
The imaging system is designed to detect extremely weak signals from surface-enhanced Raman scattering (SERS) nanoparticles that are engineered to attach to tumor markers. Once these nanoparticles are applied to a sample or to the area being examined, the system reads their Raman signal and automatically highlights regions that are more likely to contain tumor tissue.
"Traditional methods for cancer-related diagnosis are time-consuming and labor-intensive because they require staining tissue samples and having a pathologist look for any abnormalities," said research team leader Zhen Qiu from the Institute for Quantitative Health Science and Engineering (IQ), Michigan State University. "While our system would not immediately replace pathology, it could serve as a rapid screening tool to accelerate diagnosis."
This technology could eventually enable portable or intraoperative devices that enable clinicians to detect cancers at earlier stages, improve the accuracy of biopsy sampling and monitor disease progression through less invasive testing.
